multiple myeloma

Johnson & Johnson submits EMA application for TECVAYLI monotherapy in relapsed/refractory multiple myeloma, citing 71% risk reduction in disease progression or death versus standard care.

Tempest Therapeutics partners with Cincinnati Children's for TPST-2003 manufacturing, targeting U.S. registrational study launch in 2026 following strong interim trial results.

Abecma CAR-T therapy market surging on rising myeloma cases and regulatory wins. BMS-backed treatment faces headwinds from tariffs but eyes earlier-line expansion.

FDA approves J&J's Tecvayli plus Darzalex Faspro for multiple myeloma with 83.3% three-year survival rate, expanding drug's label.

Gilead acquires oncology firm Arcellx for $7.8 billion in cash, adding CAR T-cell cancer therapy to its pipeline. Deal expected to close Q4 2024.

Gilead acquires Arcellx for $7.8B to expand CAR-T therapy portfolio, strengthening oncology pipeline and cell therapy capabilities.

Gilead acquires Arcellx for $7.8B to gain CAR-T therapy anito-cel for multiple myeloma, with FDA approval expected by late 2026.

Starton launches Phase 2a trial for subcutaneous lenalidomide delivery in multiple myeloma, comparing three dose levels against standard oral Revlimid treatment.